A5048880781- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Synthesis and Biological Evaluation
- T-cell and B-cell Immunology
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- Nanowire Synthesis and Applications
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Virus-based gene therapy research
- Calcium signaling and nucleotide metabolism
- Inflammation biomarkers and pathways
- Inflammatory Biomarkers in Disease Prognosis
- Advancements in Semiconductor Devices and Circuit Design
- Immune cells in cancer
- Silicon Carbide Semiconductor Technologies
Amsterdam University Medical Centers
2019-2024
Cancer Center Amsterdam
2019-2024
Amsterdam UMC Location Vrije Universiteit Amsterdam
2020-2024
Vrije Universiteit Amsterdam
2021-2022
University of Crete
2015-2016
Abstract The role of the different circulating regulatory T-cells (Treg) subsets, as well their correlation with clinical outcome non-small cell lung cancer (NSCLC) patients is poorly understood. Peripheral blood from 156 stage III/IV chemotherapy-naive NSCLC and 31 healthy donors (HD) was analyzed flow cytometry for presence functionality CD4 + Treg subsets (naive, effector terminal effector). Their frequencies were correlated outcome. All exhibited highly suppressive activity by TGF-β...
Combination of a CAR and chimeric costimulatory receptor augments cytotoxicity durability T cells elimination antigen-low tumors.
Due to the CD1d restricted recognition of altered glycolipids, Vα24-invariant natural killer T (iNKT) cells are excellent tools for cancer immunotherapy with a significantly reduced risk graft-versus-host disease when applied as off-the shelf-therapeutics across Human Leukocyte Antigen (HLA) barriers. To maximally harness their therapeutic potential multiple myeloma (MM) treatment, we here armed iNKT chimeric antigen receptors (CAR) directed against MM-associated CD38 and plasma cell...
Abstract Purpose: The microenvironment of multiple myeloma (MM) can critically impair therapy outcome, including immunotherapies. In this context, we have earlier demonstrated that bone marrow mesenchymal stromal cells (BMMSC) protect MM against the lytic machinery MM-reactive cytotoxic T (CTL) and daratumumab-redirected natural killer (NK) through upregulation antiapoptotic proteins Survivin Mcl-1 in cells. Here, investigated significance mode immune escape on engineered to express chimeric...
The success of B-cell maturation antigen (BCMA)-specific chimeric receptor (CAR) T cells illustrates the potential this novel therapy for multiple myeloma. Nonetheless, broadening CAR T-cell beyond BCMA requires inventive strategies as there are only a few myeloma- or plasma cell-specific target antigens. We investigated feasibility achieving myeloma specificity by dual-split CD38/CD138 targeting, whereby stimulatory and costimulatory signals activation split into two separate (sCAR) CARs...
The past decades have illustrated the power of T-cell engineering in development new and successful cell therapies, such as chimeric antigen receptor (CAR) T-cells. Despite clinical success hematological malignancies, it also becomes increasingly clear that additional will be required to improve efficacy safety expand application solid tumors. Engineering is most often achieved by viral delivery transgenes, however, vector capacity limitations make efficient reproducible generation multi...
<p>Supplemental Figures</p>
<div>Abstract<p>Purpose: The success of BCMA-specific chimeric antigen receptor (CAR) T-cells illustrates the potential this novel therapy for multiple myeloma (MM). Nonetheless, broadening CAR T-cell beyond BCMA requires inventive strategies as there are only a few MM- or plasma cell-specific target antigens. We investigated feasibility achieving MM specificity by dual-split CD38/CD138 targeting, whereby stimulatory and costimulatory signals activation split into two separate...
<p>Supplemental Figures</p>
Abstract In our previous study, high levels of one granulocytic (G-MDSC) and two monocytic (M-MDSCs) subpopulations immunosuppressive MDSCs were found their overexpression was correlated with worse prognosis in NSCLC patients. Using flow cytometry, the impact chemotherapy on percentages functionality M-MDSC (CD14+CD15-CD11b+CD33+HLA-DR-Lin- CD14+CD15+CD11b+ CD33+HLA-DR-Lin-) G-MDSC (CD14-CD15+CD11b+CD33+HLA-DR-Lin-) evaluated peripheral blood patients (n=141) prior to after 3rd 6th cycle...
<div>Abstract<p>Purpose: The success of BCMA-specific chimeric antigen receptor (CAR) T-cells illustrates the potential this novel therapy for multiple myeloma (MM). Nonetheless, broadening CAR T-cell beyond BCMA requires inventive strategies as there are only a few MM- or plasma cell-specific target antigens. We investigated feasibility achieving MM specificity by dual-split CD38/CD138 targeting, whereby stimulatory and costimulatory signals activation split into two separate...
<p>Table providing information on scFv sequences CARs. Figures data CAR T cell phenotype, BMMSC survival, target antigen expression, cytotoxic mediator measurements, Survivin and Mcl-1 expression in MM cells, effector vivo efficacy of BCMA-CAR cells.</p>
<p>Table providing information on scFv sequences CARs. Figures data CAR T cell phenotype, BMMSC survival, target antigen expression, cytotoxic mediator measurements, Survivin and Mcl-1 expression in MM cells, effector vivo efficacy of BCMA-CAR cells.</p>
<div>AbstractPurpose:<p>The microenvironment of multiple myeloma (MM) can critically impair therapy outcome, including immunotherapies. In this context, we have earlier demonstrated that bone marrow mesenchymal stromal cells (BMMSC) protect MM against the lytic machinery MM-reactive cytotoxic T (CTL) and daratumumab-redirected natural killer (NK) through upregulation antiapoptotic proteins Survivin Mcl-1 in cells. Here, investigated significance mode immune escape on engineered...
<div>AbstractPurpose:<p>The microenvironment of multiple myeloma (MM) can critically impair therapy outcome, including immunotherapies. In this context, we have earlier demonstrated that bone marrow mesenchymal stromal cells (BMMSC) protect MM against the lytic machinery MM-reactive cytotoxic T (CTL) and daratumumab-redirected natural killer (NK) through upregulation antiapoptotic proteins Survivin Mcl-1 in cells. Here, investigated significance mode immune escape on engineered...
<p>Supplemental Figures</p>
<p>Supplemental Figures</p>
<div>AbstractPurpose:<p>The success of B-cell maturation antigen (BCMA)-specific chimeric receptor (CAR) T cells illustrates the potential this novel therapy for multiple myeloma. Nonetheless, broadening CAR T-cell beyond BCMA requires inventive strategies as there are only a few myeloma– or plasma cell–specific target antigens. We investigated feasibility achieving myeloma specificity by dual-split CD38/CD138 targeting, whereby stimulatory and costimulatory signals activation...